Compare VNRX & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | NVNO |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 16.7M |
| IPO Year | N/A | N/A |
| Metric | VNRX | NVNO |
|---|---|---|
| Price | $0.26 | $0.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 501.1K |
| Earning Date | 11-13-2025 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,007.00 | N/A |
| Revenue This Year | $55.33 | N/A |
| Revenue Next Year | $493.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.48 | N/A |
| 52 Week Low | $0.23 | $0.30 |
| 52 Week High | $0.94 | $5.62 |
| Indicator | VNRX | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 36.50 | 35.97 |
| Support Level | $0.23 | $0.30 |
| Resistance Level | $0.30 | $0.37 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 31.32 | 29.01 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.